2633.HK HKSE
Jacobson Pharma Corporation Limited
1W: +1.6%
1M: -2.9%
3M: -9.4%
YTD: -23.8%
1Y: -31.9%
3Y: +26.1%
5Y: +95.6%
HK$0.96 ($0.12)
+0.00 (+0.00%)
Weekly Expected Move ±3.7%
HK$1
HK$1
HK$1
HK$1
HK$1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$527M
+8.8% ▲
5Y CAGR: +7.0%
Capital Expenditures
$248M
-91.8% ▼
5Y CAGR: +24.1%
Free Cash Flow
$278M
-21.5% ▼
5Y CAGR: -0.9%
Dividends Paid
$60M
+36.4% ▲
Buybacks
$0
+100.0% ▲
Net Change in Cash
$97M
+118.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $174M | $178M | $251M | $319M | $374M |
| Depreciation & Amort. | $192M | $193M | $184M | $157M | $144M |
| Stock-Based Comp. | $0 | $0 | $19M | $19M | $15M |
| Change in Working Capital | -$212K | -$443K | $87M | -$14M | -$4M |
| Other Non-Cash Items | $46M | $40M | $408M | $3M | -$2M |
| Operating Cash Flow | $411M | $410M | $648M | $484M | $527M |
| — Investing Activities — | |||||
| Capital Expenditures | -$63M | -$64M | -$63M | -$130M | -$248M |
| Acquisitions (Net) | -$200M | -$11M | $10M | $9M | -$46M |
| Investment Purchases | -$144M | -$51M | -$2M | $0 | -$17M |
| Investment Sales | $51M | $74M | $10M | $135M | $0 |
| Other Investing | -$19M | -$510K | -$73M | $28M | $14M |
| Investing Cash Flow | -$375M | -$53M | -$44M | $43M | -$298M |
| — Financing Activities — | |||||
| Net Debt Issuance | $24M | -$261M | $172M | -$758M | $9M |
| Stock Repurchased | -$2M | $0 | -$32M | -$8M | $0 |
| Dividends Paid | -$63M | -$52M | -$104M | -$94M | -$60M |
| Other Financing | -$89M | -$45M | -$72M | -$233M | -$74M |
| Financing Cash Flow | $21M | -$358M | -$46M | -$1.1B | -$131M |
| Net Change in Cash | $62M | -$2M | $558M | -$524M | $97M |
| Cash End of Period | $480M | $479M | $1.0B | $412M | $509M |
| Free Cash Flow | $348M | $346M | $585M | $355M | $278M |